Onconetix Announces 1-for-10 Reverse Stock Split Effective November 6, 2026

2026-10-26

Investivoq

Onconetix, Inc. announced a one-for-ten reverse stock split effective November 6, 2026, reducing outstanding shares significantly.

Investivoq AI Summary

Onconetix, Inc. has announced a one-for-ten reverse stock split of its common stock, set to take effect on November 6, 2026, at 12:01 a.m. Eastern Time. This move will reduce the outstanding shares from approximately 5.89 million to about 588,677 shares, although the number of authorized shares will remain unchanged at 250 million. The company's common stock will continue to trade under the symbol "ONCO," and a new CUSIP number, 68237Q500, has been assigned for the shares. Fractional shares will not be issued; instead, cash payments will be made to stockholders due to fractional shares. The reverse split aims to not affect the percentage ownership of existing stockholders or the rights and privileges of the common stock holders, while adjustments will be made to outstanding options and securities accordingly. Onconetix focuses on developing oncology solutions, including an in vitro diagnostic test for prostate cancer.

Potential Positives

The approval of a one-for-ten (1-for-10) reverse stock split may help improve the market perception of Onconetix’s stock by increasing its share price, making it more appealing to institutional investors.
Reducing the number of outstanding shares from approximately 5,886,774 to about 588,677 can enhance the liquidity of the stock and reduce volatility.
The reverse stock split allows the company to maintain its listing on Nasdaq, which is crucial for attracting investor interest and maintaining credibility in the market.
Onconetix continues to focus on its innovative oncology solutions, including the anticipated marketing of Proclarix® as a lab-developed test in the U.S., which can contribute positively to future revenue growth.

Potential Negatives

The announcement of a reverse stock split may signal financial instability or declining company performance, potentially leading to negative investor sentiment.
The reduction in shares outstanding might create volatility in the stock price and could lead to decreased liquidity for existing shareholders.
The reverse stock split does not address any underlying issues the company may be facing, which could raise concerns among investors about the company's long-term viability.

FAQ

What is the effective date of Onconetix's reverse stock split?

The reverse stock split will become effective at 12:01 a.m. Eastern Time on November 6, 2026.

How will Onconetix's reverse stock split affect investors?

What is the new CUSIP number for Onconetix stock?

The new CUSIP number assigned in connection with the reverse stock split is 68237Q500.

Will the reverse stock split change Onconetix's authorized shares?

No, the number of authorized shares will remain at 250,000,000 shares after the reverse stock split.

How will fractional shares be handled during the reverse split?

No fractional shares will be issued; stockholders will receive cash payments for any fractional shares owed.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

EARLY ACCESS

Receive ONCO Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ONCO Hedge Fund Activity

We have seen 6 institutional investors add shares of $ONCO stock to their portfolio, and 3 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HRT FINANCIAL LP added 51,398 shares (+inf%) to their portfolio in Q2 2026, for an estimated $58,079
XTX TOPCO LTD added 13,548 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,309
GEODE CAPITAL MANAGEMENT, LLC removed 11,854 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $13,395
CITIGROUP INC removed 1,717 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,940
UBS GROUP AG removed 1,580 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,785
TOWER RESEARCH CAPITAL LLC (TRC) added 145 shares (+inf%) to their portfolio in Q2 2026, for an estimated $163
HOLLENCREST CAPITAL MANAGEMENT added 100 shares (+inf%) to their portfolio in Q2 2026, for an estimated $112

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

Full Release

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com .

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com